Trial Profile
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis: A Multi-cohort, Multi-center Clinical Trial (ALTER-G-001)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Capecitabine; Cisplatin; Docetaxel; Oxaliplatin; Paclitaxel
- Indications Biliary cancer; Carcinoma; Colorectal cancer; Gastrointestinal cancer; Liver metastases; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ALTER-G-001
- 20 Jan 2024 Results (As of September 14, 2023, n=41) assessing efficacy and safety of anlotinib plus chemotherapy as first-line treatment for LMs GI tumors presented at the 2024 Gastrointestinal Cancers Symposium
- 20 Jan 2024 Updated results assessing anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis presented at the 2024 Gastrointestinal Cancers Symposium.
- 27 Nov 2023 Planned number of patients changed from 101 to 116.